934660-93-2 | Cobimetinib

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$18.00	$13.00
2mg	98%	in stock	$26.00	$18.00
5mg	98%	in stock	$43.00	$30.00
10mg	98%	in stock	$65.00	$46.00
50mg	98%	in stock	$184.00	$129.00
100mg	98%	in stock	$308.00	$216.00
250mg	98%	in stock	$507.00	$355.00
1g	98%	in stock	$1,402.00	$982.00

Description

• Catalog Number: AH85267
• Chemical Name: Cobimetinib
• CAS Number: 934660-93-2
• Molecular Formula: C21H21F3IN3O2
• Molecular Weight: 531.31
• MDL Number: MFCD22124461
• SMILES: Ic1ccc(c(c1)F)Nc1c(ccc(c1F)F)C(=O)N1CC(C1)(O)[C@@H]1CCCCN1

Computed Properties

• Complexity: 624
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 30
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 4
• XLogP3: 3.9

Upstream Synthesis Route

The compound [3,4-Difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl][3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl]methanone is utilized in chemical synthesis as a key intermediate in the production of complex pharmaceutical compounds. Its unique structural features and functional groups make it a valuable building block in the synthesis of drug candidates and fine chemicals. In particular, the presence of fluoro, amino, and hydroxy groups allows for versatile reactivity and selective functionalization in various synthetic pathways. This compound plays a crucial role in the strategic assembly of molecular structures with specific pharmacological activities, making it an essential tool for the development of novel drug molecules and advanced materials.

Literature

• Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes.

  Toxicology letters 20180701

• Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.

  Drug metabolism and disposition: the biological fate of chemicals 20160101

• MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy.

  Drug design, development and therapy 20160101

• Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.

  Cancer chemotherapy and pharmacology 20151101

• Cobimetinib: First Global Approval.

  Drugs 20151001

• Targeted inhibition of MEK1 by cobimetinib leads to differentiation and apoptosis in neuroblastoma cells.

  Journal of experimental & clinical cancer research : CR 20150101

• Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.

  Nature 20130912

• MEK and the inhibitors: from bench to bedside.

  Journal of hematology & oncology 20130101

• Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.

  Cancer research 20120101

• The role of BRAF V600 mutation in melanoma.

  Journal of translational medicine 20120101

• Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

  Cell 20040319

• Mutations of the BRAF gene in human cancer.

  Nature 20020627